[go: up one dir, main page]

MA71621A - Anticorps anti-tl1a pour le traitement de la colite ulcéreuse et de la maladie de crohn - Google Patents

Anticorps anti-tl1a pour le traitement de la colite ulcéreuse et de la maladie de crohn

Info

Publication number
MA71621A
MA71621A MA71621A MA71621A MA71621A MA 71621 A MA71621 A MA 71621A MA 71621 A MA71621 A MA 71621A MA 71621 A MA71621 A MA 71621A MA 71621 A MA71621 A MA 71621A
Authority
MA
Morocco
Prior art keywords
crohn
disease
treatment
ulcerative colitis
tl1a antibodies
Prior art date
Application number
MA71621A
Other languages
English (en)
Inventor
Alexandra Kropotova
Shyam Bhaskerbhai MEHTA
Stanislav STOYANOV
Andrijana RADIVOJEVIC
Original Assignee
Cephalon Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Llc filed Critical Cephalon Llc
Publication of MA71621A publication Critical patent/MA71621A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MA71621A 2022-07-27 2023-07-27 Anticorps anti-tl1a pour le traitement de la colite ulcéreuse et de la maladie de crohn MA71621A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263369591P 2022-07-27 2022-07-27
US202263387786P 2022-12-16 2022-12-16
EP23757805.9A EP4562040A1 (fr) 2022-07-27 2023-07-27 Anticorps anti-tl1a pour le traitement de la colite ulcéreuse et de la maladie de crohn
PCT/US2023/071103 WO2024026395A1 (fr) 2022-07-27 2023-07-27 Anticorps anti-tl1a pour le traitement de la colite ulcéreuse et de la maladie de crohn

Publications (1)

Publication Number Publication Date
MA71621A true MA71621A (fr) 2025-05-30

Family

ID=87747839

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71621A MA71621A (fr) 2022-07-27 2023-07-27 Anticorps anti-tl1a pour le traitement de la colite ulcéreuse et de la maladie de crohn

Country Status (12)

Country Link
US (1) US20250270336A1 (fr)
EP (1) EP4562040A1 (fr)
JP (1) JP2025526402A (fr)
KR (1) KR20250044336A (fr)
CN (1) CN119894931A (fr)
AU (1) AU2023314783A1 (fr)
CA (1) CA3262839A1 (fr)
CL (1) CL2025000202A1 (fr)
IL (1) IL318428A (fr)
MA (1) MA71621A (fr)
MX (1) MX2025001041A (fr)
WO (1) WO2024026395A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025038473A1 (fr) 2023-08-11 2025-02-20 Paragon Therapeutics, Inc. Protéines de liaison à tl1a et procédés d'utilisation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
MX2014003689A (es) 2011-09-30 2014-12-05 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos contra tl1a y sus usos.
SG11201602671WA (en) * 2013-11-13 2016-05-30 Pfizer Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
EP4296285A3 (fr) * 2018-04-30 2024-02-28 Cedars-Sinai Medical Center Procédés et systèmes de sélection et de traitement de patients souffrant de maladies inflammatoires
AU2020275413A1 (en) * 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
PH12022550167A1 (en) * 2019-08-16 2023-05-08 Regeneron Pharma High concentration anti-c5 formulations
KR20230025898A (ko) 2020-06-26 2023-02-23 화이자 인코포레이티드 Tl1a 항체를 사용하여 염증성 장 질환을 치료하는 방법

Also Published As

Publication number Publication date
KR20250044336A (ko) 2025-03-31
JP2025526402A (ja) 2025-08-13
MX2025001041A (es) 2025-04-02
EP4562040A1 (fr) 2025-06-04
CA3262839A1 (fr) 2024-02-01
CN119894931A (zh) 2025-04-25
US20250270336A1 (en) 2025-08-28
AU2023314783A1 (en) 2025-03-06
WO2024026395A1 (fr) 2024-02-01
CL2025000202A1 (es) 2025-07-11
IL318428A (en) 2025-03-01

Similar Documents

Publication Publication Date Title
EP3414573A4 (fr) Nouveaux anticorps monoclonaux anti-lam et anti-pim6/lam pour le diagnostic et le traitement d'infections par le bacille de koch
EP3856478A4 (fr) Formulations pour le traitement de la maladie de l'oeil sec
EP4297871A4 (fr) Procédés et compositions pour le traitement de l'agitation
EP4157324A4 (fr) Analogue de pth pour le traitement de l'hypoparathyroïdie
MA54132A (fr) Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23
EP3854875A4 (fr) Anticorps monoclonal humain se fixant spécifiquement a hmgb1 humain, et composition pharmaceutique pour le traitement ou la prévention de la maladie d'alzheimer contenant ledit anticorps monoclonal humain
GEAP202516710A (en) Anti-cd30l antibodies and uses thereof
EP4121048A4 (fr) Agonistes du récepteur de farnésoïde x pour le traitement d'une maladie
MA71621A (fr) Anticorps anti-tl1a pour le traitement de la colite ulcéreuse et de la maladie de crohn
EP4297868A4 (fr) Utilisation d'aprépitant pour le traitement de la maladie d'alzheimer
MA54525A (fr) Anticorps bispécifiques clec12axcd3 et méthodes de traitement d'une maladie
EP3876967A4 (fr) Microbiote thérapeutique pour le traitement et/ou la prévention d'une dysbiose
EP4157341A4 (fr) Peptides pour la prévention et le traitement de la covid-19
CA3236794A1 (fr) Compositions et methodes pour le traitement de l'epilepsie
EP4210750A4 (fr) Méthodes et agents thérapeutiques pour le traitement d'un infarctus du myocarde
EP4340881A4 (fr) Anticorps pour le traitement d'alpha-synucléinopathies
EP3802568A4 (fr) Agents thérapeutiques peptidiques pour le traitement de la maladie d'alzheimer et d'états apparentés
EP4052694A4 (fr) Composition de gouttes oculaires pour la prévention ou le traitement d'une maladie oculaire
EP3616723A4 (fr) Procédé de traitement de la myopie et son application dans la préparation d'un médicament
EP4331593A4 (fr) Composition pharmaceutique pour la prévention ou le traitement de la maladie de parkinson, et son procédé de préparation
EP4171582A4 (fr) Médicament polymère pour le traitement de l'hyperkaliémie et son procédé de préparation
EP4230652A4 (fr) Anticorps anti-oscar pour la prévention ou le traitement de l'arthrose
MA71321A (fr) Anticorps bispécifiques anti-pcrv et psl pour le traitement de la bronchiectasie
EP4340896A4 (fr) Méthodes et compositions pour le traitement d'une maladie néovasculaire oculaire
EP4103179A4 (fr) Polythérapie pour le traitement de la sclérose latérale amyotrophique à l'aide de pridopidine et d'un autre agent actif